Ulcerative colitis and Crohn’s disease are grouped together as inflammatory bowel disease, and they share a great deal: the same immune mechanism in outline, overlapping genetics, many of the same drugs and much of the same daily experience.
But they are not the same condition, and the differences are not cosmetic. Two things separate them, and almost everything else follows from those two.
Where the inflammation is. Ulcerative colitis affects the colon and rectum, and nothing else. Crohn’s can affect any part of the digestive tract from the mouth to the anus.
How deep it goes. Ulcerative colitis inflames the mucosa — the innermost lining — in one continuous stretch. Crohn’s inflames the full thickness of the bowel wall, in patches with normal tissue between them.
The differences at a glance
| Ulcerative colitis | Crohn’s disease | |
|---|---|---|
| Where | Colon and rectum only | Anywhere, mouth to anus; commonly the terminal ileum |
| Pattern | Continuous, always from the rectum upwards | Patchy, with healthy “skip” areas between |
| Depth | Mucosa only | Full thickness of the wall |
| Blood in stool | Very common, often the first sign | Less common |
| Typical pain | Crampy, lower left | Crampy, lower right |
| Weight loss | Less marked | Common, from malabsorption |
| Perianal disease | Rare | Common — fistulas, abscesses, skin tags |
| Strictures and fistulas | Rare | Common, from full-thickness inflammation |
| Mouth ulcers | Occasional | Common |
| Smoking | Associated with lower risk | Clearly makes it worse |
| Surgery | Removing the colon is curative | No operation cures it |
| ICD-10 code | K51 | K50 |
Why the depth difference drives everything
This is the single most useful thing to understand, because it explains why the two conditions behave so differently.
Because Crohn’s inflammation goes through the whole wall, repeated cycles of inflammation and healing leave scar tissue through the full thickness. That produces strictures — narrowed segments that can obstruct — and fistulas, abnormal tunnels burrowing from the bowel into another loop of bowel, the bladder, the vagina or the skin. These are structural problems, and medication does not reverse them.
Because ulcerative colitis stays superficial, strictures and fistulas are rare. The inflammation ulcerates the lining and bleeds readily, which is why visible blood is such a prominent early symptom. The characteristic complications are different: acute severe colitis needing hospital treatment, and toxic megacolon, in which the colon dilates dangerously.
And because colitis is confined to one organ, there is somewhere to remove. Take out the colon and the disease is gone. Remove a diseased segment of small bowel in Crohn’s and the inflammation characteristically returns at the join.
Symptoms: the distinguishing details
Both cause diarrhoea, abdominal pain and fatigue. The details differ.
More typical of ulcerative colitis:
- Blood and mucus in the stool, often from the very beginning
- Urgency, and tenesmus — straining with little result, sometimes passing only blood and mucus
- Pain low on the left, building before a bowel movement and easing afterwards
- Symptoms that worsen steadily as inflammation spreads further up the colon
More typical of Crohn’s:
- Pain low on the right, where the terminal ileum sits
- Unintended weight loss and nutritional deficiencies, because the small intestine does the absorbing
- Recurrent mouth ulcers
- Pain, swelling, a lump or discharge around the anus — fairly specific to Crohn’s
- Nausea and vomiting if a narrowed segment is partly obstructing
How they are told apart
The route is similar for both:
- Faecal calprotectin to confirm inflammation rather than irritable bowel syndrome
- Blood tests for anaemia, CRP, ferritin and nutritional markers
- Stool culture to exclude infection
- Colonoscopy with biopsies — the test that actually distinguishes them
At colonoscopy the difference is usually visible. Ulcerative colitis shows continuous inflammation starting at the rectum, with a clear upper border. Crohn’s shows patchy inflammation, often deep linear ulcers giving a cobblestone appearance, frequently with a normal rectum.
Biopsies settle it where the appearance does not: granulomas, small clusters of immune cells, are found in some Crohn’s cases and effectively never in ulcerative colitis.
If the small bowel needs assessing — for Crohn’s, where the colonoscope cannot reach — MRI enterography or a capsule endoscopy is added. Ulcerative colitis does not require small bowel imaging, which is one reason the diagnostic pathway is often shorter.
Where treatment diverges
The drug lists overlap considerably — anti-TNF agents, vedolizumab, ustekinumab, thiopurines and steroids all appear in both. The differences are worth knowing:
- Aminosalicylates such as mesalazine are a mainstay of ulcerative colitis, both for settling flares and for long-term maintenance, where they also reduce bowel cancer risk. In Crohn’s their role is marginal.
- Rectal treatments — suppositories and enemas — are highly effective in ulcerative colitis, because the rectum is always involved. They have little place in most Crohn’s.
- Exclusive enteral nutrition, a liquid-only diet, induces remission in Crohn’s and is first-line for children. It is not a standard colitis treatment.
- JAK inhibitors such as tofacitinib were licensed for ulcerative colitis first.
- Stopping smoking is a core part of Crohn’s management. In ulcerative colitis it still matters for general health, but it may make the colitis harder to control.
Long-term outlook
Both conditions carry a raised risk of bowel cancer with long-standing, extensive disease, and both warrant surveillance colonoscopy starting around eight to ten years after diagnosis.
Each has its own associated conditions. Primary sclerosing cholangitis, a chronic liver disease, is far more strongly linked to ulcerative colitis, and its presence means more intensive cancer surveillance. Crohn’s carries higher rates of gallstones, kidney stones and vitamin B12 deficiency, reflecting small bowel involvement.
Life expectancy in both is close to that of the general population. Most people with either condition work, travel, have children and reach long periods of remission.
Why the label matters
It is reasonable to wonder whether the distinction makes any practical difference when the day-to-day experience is so similar. It does, in four ways:
- Which drugs are worth trying — particularly mesalazine and rectal treatments
- What complications to watch for — strictures and fistulas versus severe flares and megacolon
- What surgery can offer — curative in colitis, not in Crohn’s
- What surveillance you need — small bowel imaging, liver monitoring, cancer screening intervals
If your diagnosis is currently IBD-unclassified, that is a recognised and reasonably common position rather than a sign that something has been missed. Treatment proceeds on the pattern as it stands, and the picture usually clarifies with time.
